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Abstract
Introduction Angiogenesis is an important process in the
development of destructive synovial pannus in rheumatoid
arthritis (RA). The ITGAV  +gene encodes a cell cycle-
associated antigen, integrin ανβ 3, which plays a role in RA
angiogenesis. Previously, two independent studies identified an
association between the major allele of the ITGAV  single-
nucleotide polymorphism (SNP) rs3738919  and RA. We
therefore tested this association in an independent study using
New Zealand (NZ) and Oxford (UK) RA case control samples.
Methods We compared genotype frequencies in 740 NZ
Caucasian RA patients and 553 controls genotyped for
rs3738919, using a polymerase chain reaction-restriction
fragment length polymorphism assay. A TaqMan genotyping
SNP assay was used to type 713 Caucasian RA patients and
515 control samples from Oxford for the rs3738919 variant.
Association of rs3738919 with RA was tested in these two
sample sets using the chi-square goodness-of-fit test. The
Mantel-Haenszel test was used to perform a meta-analysis,
combining the genetic results from four independent Caucasian
case control cohorts, consisting of 3,527 cases and 4,126
controls. Haplotype analysis was also performed using SNPs
rs3911238,  rs10174098  and  rs3738919  in the Wellcome
Trust Case Control Consortium, NZ and Oxford case control
samples.
Results We found no evidence for association between ITGAV
and RA in either the NZ or Oxford sample set (odds ratio [OR]
= 0.88, Pallelic  = 0.11 and OR = 1.18, Pallelic  = 0.07,
respectively). Inclusion of these data in a meta-analysis (random
effects) of four independent cohorts (3,527 cases and 4,126
controls) weakens support for the hypothesis that rs3738919
plays a role in the development of RA (ORcombined = 0.92, 95%
confidence interval 0.80 to 1.07; P  = 0.29). No consistent
haplotype associations were evident.
Conclusions Association of ITGAV SNP rs7378919 with RA
was not replicated in NZ or Oxford case control sample sets.
Meta-analysis of these and previously published data lends
limited support for a role for the ITGAV in RA in Caucasians of
European ancestry.
ACR: American College of Rheumatology; CI: confidence interval; CTLA4: cytotoxic T-lymphocyte antigen 4; ITGAV: integrin ανβ3; NZ: New Zea-
land; OR: odds ratio; ORallelic: odds ratio for allele frequency difference; PTPN22: protein tyrosine phosphatase non-receptor 22; RA: rheumatoid 
arthritis; RF: rheumatoid factor; SNP: single-nucleotide polymorphism; WTCCC: Wellcome Trust Case Control Consortium.Arthritis Research & Therapy    Vol 11 No 5    Hollis-Moffatt et al.
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Introduction
Rheumatoid arthritis (RA) is a common systemic autoimmune
disease characterised by chronic synovial inflammation lead-
ing to the formation of invasive, destructive pannus. The exten-
sive formation of new blood vessels within the affected joint
(hyperangiogenesis) is an important component of pannus for-
mation [1].
A heritable component to RA is supported by twin studies [2]
and the markedly increased sibling recurrence risk (λs = 5 to
7.2) compared with the general population [3]. Association
with the HLA-DRB1 locus is well established, with many other
loci also incriminated. These include the protein tyrosine phos-
phatase non-receptor 22 (PTPN22) gene [4,5], cytotoxic T-
lymphocyte antigen 4 (CTLA4) [6], an intergenic region on
human chromosome 6 [7,8], signal transducer and activator of
transcription 4 (STAT4) [9], the tumour necrosis factor recep-
tor-associated factor 1 region (TRAF/C5) [7,10,11] and
CD40, CCL21 and IL2RB [12,13].
The integrin ανβ3 (ITGAV) locus contains 30 exons spanning
more than 90 kb of genomic DNA on human chromosome
2q31. It encodes the αν subunit of the cell cycle-associated
antigen, integrin ανβ3, which plays a major role in RA angio-
genesis. Angiogenesis is stimulated in RA by the increased
metabolic demand of the pathologically active synovial tissues
[1,14-16]. Potentially, inhibition of this angiogenesis might
suppress the destructive activities of pannus and even control
disease activity [17]. This is supported by studies in animal
models in which injection of ανβ3 antagonists has shown inhi-
bition of neovascularisation and attenuation of joint inflamma-
tion [18].
A previous genome-wide linkage scan suggested 19 non-HLA
regions contributing to RA in a French population [19]. One of
these regions, on human chr2q31, contains the ITGAV gene
(CD51). Subsequently, Jacq and colleagues [20] demon-
strated an association between RA and the ITGAV
rs3738919 C allele in a French Caucasian population (odds
ratio for allele frequency difference [ORallelic] = 0.77, 95%
confidence interval [CI] 0.63 to 0.94). Significant association
with the rs3738919  C allele was also demonstrated from
imputed data by the Wellcome Trust Case Control Consor-
tium (WTCCC) (ORallelic = 0.91, 95% CI 0.83 to 1.00) [21].
Collectively, these studies suggest a role for ITGAV in RA and
justify further investigation of this locus. We therefore tested
this association in an independent study using New Zealand
(NZ) and Oxford (UK) RA case control samples.
Materials and methods
Study subjects
The NZ population-based Caucasian sample consists of 740
RA patients fulfilling the American College of Rheumatology
(ACR) criteria for RA [22]. Of the patients for whom data were
available, 34.3% (234/683) were male, 82.9% (538/649)
were rheumatoid factor (RF)-positive, 68.1% (275/404) were
anti-cyclic citrullinated peptide (anti-CCP)-positive and 79.4%
(576/725) carried the HLA-DRB1  shared epitope. Ethical
approval for recruitment of cases was given by the New Zea-
land Multi-Region Ethics Committee, and recruitment of the
controls was approved by the Lower South Ethics Committee.
All patients provided written informed consent for the collec-
tion of samples and subsequent analysis. The control sample
consisted of 553 NZ European Caucasians (226/552 male;
40.9%) with no history of autoimmune disease.
The 713 UK patients were recruited in Oxford, with informed
consent from attendees at the rheumatology outpatient clinic
at the Nuffield Orthopaedic Centre. All fulfilled the 1987 ACR
criteria for RA; the average age of onset was 48 years, 28%
were male, 77% were positive for RF and 77% carried the
HLA-DRB1 shared epitope. Healthy ethnically matched con-
trols (n = 515) were recruited from the same locale as that of
blood donors. Approval for the study was given by the Oxford
Research Ethics Committee (OxRec number C02.032).
DNA extraction and genotyping
DNA was extracted from peripheral blood samples of the RA
patients and controls by means of guanidine isothiocyanate-
chloroform extraction methods. NZ study participants were
genotyped for the ITGAV  single-nucleotide polymorphism
(SNP) rs3738919 using a polymerase chain reaction-restric-
tion fragment length polymorphic SNP genotyping assay as
follows: forward primer CACTTTCTGTAAATTAGTGTTA-
GATCAAAAGG and reverse primer GCTTATAACTCACAAT-
TCAGATTTTTGCC (primers from Sigma-Genosys, Sydney,
Australia). The C allele (major allele) of the rs3738919 prod-
uct (286 base pairs) was digested using the AluI restriction
enzyme to form fragments of 223 and 63 base pairs. Oxford
study participants were genotyped for rs3738919 using the
TaqMan genotyping assay C___1278131_1, and both the NZ
and Oxford samples were genotyped for the rs10174098 and
rs3911238 ITGAV variants using the TaqMan genotyping
assays C__30567648_10 and C___7617051_10, respec-
tively, from Applied Biosystems (Scoresby, Australia).
Although the imputed rs3738919  data were available and
were previously reported by Ahnert and Kirsten [21], we reim-
puted rs3738919 genotypes in order to provide information
on imputation parameters. RA case and control genotypes
were imputed from the WTCCC dataset using IMPUTE soft-
ware [23]. Genotypes were imputed from 89% of cases (n =
1,659) and 90% of controls (n = 2,639) using a 7-Mb region
and a calling threshold of 0.7.
Statistical analysis
An a priori power calculation was made based on the com-
bined French [20] and WTCCC [21] OR (ORallelic = 1.16),
using 800 cases and 600 controls with a major allele fre-
quency of 65%. The power to detect association ofAvailable online http://arthritis-research.com/content/11/5/R152
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Table 1
Allele and genotype distribution of rs3738919
Cohort Case, number (frequency) Control, number (frequency) P value OR (95% CI)
New Zealand
Minor allele 501 (0.339) 408 (0.369) 0.11 0.88 (0.75-1.03)
Genotype 1,1 326 (0.38) 210 (0.38) - 1
1,2 327 (0.44) 278 (0.50) 0.021 0.76 (0.60-0.96)
2,2 87 (0.12) 65 (0.12) 0.43 0.86 (0.60-1.24)
HWE 0.72 0.061
Dominant 0.028
Additive 0.10
Recessive 0.99
Oxford, UK
Minor allele 506 (0.355) 329 (0.319) 0.068 1.17 (0.99-1.39)
Genotype 1,1 300 (0.42) 235 (0.46) - 1
1,2 319 (0.45) 231 (0.45) 0.52 1.08 (0.85-1.38)
2,2 93 (0.13) 49 (0.10) 0.044 1.49 (1.01-2.19)
HWE 0.60 0.47
Dominant 0.22
Additive 0.069
Recessive 0.055
WTCCC
Minor allele 1,141 (0.344) 1,928 (0.365) 0.044 0.91 (0.83-1.00)
Genotype 1,1 708 (0.43) 1,044 (0.40) - 1
1,2 761 (0.46) 1,262 (0.48) 0.079 0.89 (0.78-1.01)
2,2 190 (0.11) 333 (0.13) 0.094 0.84 (0.69-1.03)
HWE 0.50 0.11
Dominant 0.043
Additive 0.041
Recessive 0.26
Jacq et al. [20]
Minor allele 292 (0.352) 343 (0.413) 0.01 0.77 (0.63-0.94)
Genotype 1,1 166 (0.40) 148 (0.36) - 1
1,2 206 (0.50) 191 (0.46) 0.80 0.96 (0.71-1.29)
2,2 43 (0.10) 76 (0.18) 0.002 0.50 (0.33-0.78)
HWE 0.0718 0.30
Dominant 0.20
Additive 0.0096
Recessive 0.0011
Combined
Minor allele 2,440 (0.346) 3,008 (0.365) 0.014 0.92 (0.86-0.98)
Genotype 1,1 1,500 (0.43) 1,637 (0.40) - 1
1,2 1,614 (0.46) 1,966 (0.48) 0.028 0.90 (0.81-0.99)
2,2 413 (0.12) 523 (0.13) 0.046 0.86 (0.74-1.00)
HWE 0.51 0.083
Dominant 0.011
Additive 0.013
Recessive 0.20
CI, confidence interval; HWE, Hardy-Weinberg equilibrium P value; OR, odds ratio; WTCCC, Wellcome Trust Case Control Consortium.Arthritis Research & Therapy    Vol 11 No 5    Hollis-Moffatt et al.
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rs3738919 to RA using either the NZ or Oxford sample set
was estimated to be 47%, using α = 0.05. ITGAV SNPs were
tested for deviation from Hardy-Weinberg equilibrium in both
the control and RA samples using a chi-square goodness-of-
fit test. The significance of differences in the minor allele fre-
quency between RA patients and controls, and stratified
patients, was assessed using the chi-square goodness-of-fit
test.
Of the five ITGAV  SNPs (rs3911238,  rs2887827,
rs10174098, rs13006571 and rs16828163) genotyped by
the WTCCC and rs3738919, only three (rs3911238,
rs10174098 and rs3738919) were required to tag all major
haplotypes defined by the six variants. Haplotype association
analysis was performed using the SHEsis software package
[24], which uses a full-precise-iteration algorithm to construct
haplotypes and estimate haplotype frequencies.
Meta-analysis combining the French [20], WTCCC [25], NZ
and Oxford samples was performed using STATA version 8.0
(StataCorp LP, College Station, TX, USA). The Mantel-Haen-
szel test was used to estimate the average conditional com-
mon OR between the four independent sample sets and to
test for any heterogeneity between the four groups using both
fixed and random effects. R software [26] was used to perform
the Cochran-Armitage trend test to determine recessive, addi-
tive and dominant trend values (Table 1).
Results
Analysis of rs3738919 in New Zealand and Oxford 
Caucasian rheumatoid arthritis samples
We genotyped rs3738919  across the NZ and Oxford RA
case control cohorts and found no evidence for an association
between ITGAV and RA (Pallelic = 0.11; ORallelic = 0.88 [95%
CI 0.75 to 1.03] and Pallelic = 0.07; ORallelic = 1.17 [95% CI
0.99 to 1.39], respectively) (Table 1). The direction of the NZ
allele distribution is consistent with the previous French [20]
and WTCCC [21] data, with the minor allele under-repre-
sented in the case groups in all three cohorts (Table 1). How-
ever, the allele distribution in the Oxford RA cohort differs in
that the minor allele is over-represented in the patient group
compared with the control group (Table 1).
Table 2
Three-marker haplotype analysis of ITGAV single-nucleotide polymorphisms (rs10174098, rs3911238, rs3738919) in the Wellcome 
Trust Case Control Consortium, New Zealand and Oxford sample sets
rs10174098 rs3911238 rs3738919 Case, number (frequency) Control, number (frequency) P value OR (95% CI)
WTCCC
1 1 2 866 (0.261) 1,451 (0.275) 0.19 0.94 (0.85-1.03)
2 1 1 858 (0.259) 1,382 (0.262) 0.82 0.99 (0.90-1.09)
1 2 1 792 (0.239) 1,226 (0.232) 0.43 1.04 (0.94-1.16)
1 1 1 524 (0.158) 741 (0.140) 0.021 1.15 (1.02-1.30)
2 1 2 219 (0.066) 405 (0.077) 0.070 0.85 (0.72-1.01)
New Zealand
1 1 2 357 (0.244) 260 (0.263) 0.29 0.90 (0.75~1.09)
2 1 1 364 (0.249) 240 (0.243) 0.73 1.03 (0.86~1.25)
1 2 1 359 (0.246) 223 (0.225) 0.26 1.12 (0.92~1.35)
1 1 1 241 (0.165) 170 (0.172) 0.60 0.95 (0.76~1.17)
2 1 2 110 (0.075) 73 (0.074) 0.91 1.02 (0.75~1.39)
Oxford, UK
1 1 2 310 (0.256) 252 (0.253) 0.80 1.03 (0.85-1.24)
2 1 1 306 (0.253) 262 (0.262) 0.67 0.96 (0.79-1.16)
1 2 1 335 (0.277) 251 (0.252) 0.16 1.15 (0.95-1.39)
1 1 1 158 (0.130) 162 (0.162) 0.04 0.78 (0.62-0.99)
2 1 2 78 (0.064) 57 (0.057) 0.47 1.14 (0.80-1.62)
Only haplotypes with frequency of at least 0.05 in controls are shown. CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; 
WTCCC, Wellcome Trust Case Control Consortium.Available online http://arthritis-research.com/content/11/5/R152
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Haplotype analysis
Association analysis using our imputed genotypes for
rs3738919 (P = 0.04) from the WTCCC data were consist-
ent with the previous report of an association of this SNP with
RA in the WTCCC [21]. In our analysis, we obtained imputed
genotypes from 89% of the WTCCC case control subjects.
Presumably, this reflects the influence of the low linkage dise-
quilibrium that exists between rs3738919 and the genotyped
SNPs (0.01 <r2 < 0.54 in CEU [Centre d'Etude du Polymor-
phisme Humain Utah] HapMap [27]) on confidence calls of
imputed genotypes. Haplotype analysis (Table 2) was per-
formed using the actual genotypes from ITGAV  SNPs
rs3911238 and rs10174098 (Additional data file 1) and the
imputed genotypes for rs3738919 (Table 1). One susceptibil-
ity haplotype (1-1-1), containing the major allele at each of the
three SNPs, was significantly over-represented in cases com-
pared with controls (OR = 1.15, 95% CI 1.02 to 1.30; P =
0.021).
Figure 1
Meta-analysis of the ITGAV single-nucleotide polymorphism rs3738919 in four independent rheumatoid arthritis Caucasian cohorts: Jacq and col- leagues [20], Wellcome Trust Case Control Consortium (WTCCC) [25], New Zealand and Oxford sample sets Meta-analysis of the ITGAV single-nucleotide polymorphism rs3738919 in four independent rheumatoid arthritis Caucasian cohorts: Jacq and col-
leagues [20], Wellcome Trust Case Control Consortium (WTCCC) [25], New Zealand and Oxford sample sets. (a) Fixed effects model. (b) Ran-
dom effects model. CI, confidence interval.Arthritis Research & Therapy    Vol 11 No 5    Hollis-Moffatt et al.
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Table 3
Subphenotype analysis of rs3738919 in rheumatoid arthritis patients
CC, number (frequency) CA, number (frequency) AA, number (frequency) P value
New Zealand
Gender
Male 117 (0.500) 90 (0.385) 27 (0.115) 0.026
Female 177 (0.394) 216 (0.481) 56 (0.125)
RF
Yes 232 (0.431) 239 (0.444) 67 (0.125) 0.75
No 49 (0.441) 51 (0.459) 11 (0.100)
SE
Yes 241 (0.418) 269 (0.467) 66 (0.115) 0.05
No 75 (0.503) 53 (0.356) 21 (0.141)
Oxford, UK
Gender
Male 89 (0.434) 86 (0.420) 30 (0.146) 0.55
Female 211 (0.416) 233 (0.460) 63 (0.124)
RF
Yes 227 (0.411) 247 (0.447) 78 (0.141) 0.34
No 69 (0.454) 68 (0.447) 15 (0.099)
SE
Yes 226 (0.410) 254 (0.461) 71 (0.129) 0.47
No 74 (0.457) 66 (0.407) 22 (0.136)
WTCCC
Gender
Male 180 (0.438) 187 (0.455) 44 (0.107) 0.80
Female 528 (0.423) 574 (0.460) 146 (0.117)
RF, rheumatoid factor; SE, shared epitope; WTCCC, Wellcome Trust Case Control Consortium.
Variants rs3911238 and rs10174098 were typed over the NZ
and Oxford sample sets, and association of three-marker hap-
lotypes was examined (Additional data file 1 and Table 2).
There was no support for a positive association of the 1-1-1
haplotype with RA in either the NZ or Oxford sample set. There
was a significant protective effect for this haplotype in the
Oxford samples (OR = 0.78, 95% CI 0.62 to 0.99; P  =
0.042).
Meta-analysis of ITGAV in the four independent case 
control sample sets
Meta-analysis of all four sample sets, using a fixed effects
model, revealed some evidence for an association of
rs3738919 with RA (OR = 0.92, 95% CI 0.86 to 0.99; P =
0.021) (Figure 1a). Because of evidence for heterogeneity
between the sample sets (Breslow-Day P = 0.011), a random
effects model was also used for meta-analysis; this did not
provide evidence for an association of rs3738919 with RA
(OR = 0.92, 95% CI 0.80 to 1.07; P = 0.29) (Figure 1b). The
Oxford sample set is significantly different from the other three
sample sets at rs3738919; however, the Oxford patient sam-
ple set did not have any large differences in relation to gender
(Oxford 28% male, NZ 34%, WTCCC 25%, France 13%), RF
status (Oxford 77% positive, NZ 83%, WTCCC 84%, France
75%) or inheritance of the shared epitope (Oxford 77% posi-
tive, NZ 79%, WTCCC 79%, France 79%).
Stratification according to subphenotype
The NZ and Oxford samples were stratified according to gen-
der, RF and shared epitope status (Table 3). The stratification
results did not reveal any significant differences in the
rs3738919 genotype distribution for RA patients. There wasAvailable online http://arthritis-research.com/content/11/5/R152
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a difference in the rs3738919 genotype distribution of male
and female patients in the NZ cases (P = 0.026) (Table 3).
However, a significant difference was not evident in either the
Oxford or WTCCC case sample set (P  = 0.55 and 0.80,
respectively) (Table 3).
Discussion
There was no evidence supporting a role for the ITGAV SNP
rs3738919 in the etiology of RA when the NZ and the Oxford
case control sample sets were analysed separately (P = 0.11
and 0.07, respectively) (Table 1). Trends for association were
observed in both sets of samples, but in opposing directions
(OR = 0.86 and 1.18, respectively). When all of the available
sample sets were analysed together in a random effects model
owing to the heterogeneity caused by the Oxford sample set,
there was no longer evidence for an association of rs3738919
with RA (OR = 0.92; P = 0.29). To further investigate a poten-
tial association of RA with rs3738919, genotyping in a very
large cohort will be required. The work previously undertaken
by Thomson and colleagues [8] in confirming an association
with RA of the Chr6q23 locus is an excellent example of how
this can be achieved. A sample set of this size would have
69% power (α = 0.05; OR = 0.92) to detect association at
rs3738919.
The rs3738919 ITGAV variant previously showed no associa-
tion with RA in Japanese case-control samples [28]. These
data were not included in our meta-analysis given that the
major allele was present at a considerably different frequency
in Japanese controls (0.92) than in Caucasian controls
(France, 0.58; OXFORD, 0.64; and NZ, 0.63). It is already
clear that there are genetic differences in susceptibility to RA
between the Japanese and Caucasian populations. For exam-
ple, the HLA-DRB1*0405 allele is most strongly associated
with RA in Japanese patients [29] whereas the *0401 and
*0404  alleles are more associated with RA in Caucasians
[30]. Other genes showing population-specific effects in RA
are the R620W variant of the protein tyrosine phosphatase,
PTPN22, associated with Caucasian RA [4,5] but monomor-
phic in the Japanese population [31]; CTLA4, associated with
RA in Caucasian [6] but not associated with RA in Japanese
patients [32]; peptidylarginine deiminase type 4, PADI4, asso-
ciated in Japanese patients [33,34] but very weakly in Cauca-
sians [6,35,36]; and the Fc receptor-like 3 gene variant,
FCRL3-169C, associated with RA in Japanese patients
[37,38] and in one Caucasian study [39] but not in other Cau-
casian studies [40,41]. In conclusion, we have not been able
to provide further support for the involvement of ITGAV in the
etiology of RA in Caucasians. However, it is important that fur-
ther genotyping be done in a large independent cohort to con-
firm whether ITGAV plays a role in RA.
Conclusions
In Caucasians, meta-analysis of 3,527 cases and 4,126 con-
trols does not provide further evidence for a role of the ITGAV
SNP rs3738919 in the development of RA.
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